The GLP-1 receptor agonist (GLP-1RA) market, currently dominated by pharmaceutical giants Novo Nordisk and Eli Lilly, is witnessing the emergence of smaller biotech companies poised to challenge the status quo. These companies are developing novel GLP-1RA therapies with the potential to capture significant market share and generate substantial revenue.
Altimmune is advancing pemvidutide, a GLP-1RA currently in Phase II clinical trials for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Pemvidutide is projected to launch in 2027 and is forecast to generate sales of $1.21 billion in 2030. This highlights the significant commercial potential for new entrants in the GLP-1RA space.
Structure Therapeutics is also developing an oral GLP-1RA, GSBR-1290, which is in Phase II development for obesity and type 2 diabetes. Similar to Viking Therapeutics' VK-2735, GSBR-1290 offers the convenience of oral administration. The drug is expected to launch in 2028 and is projected to generate $1.2 billion in sales by 2030.
The entry of these emerging biotechs—Viking Therapeutics, Altimmune, and Structure Therapeutics—into the GLP-1RA market underscores the dynamic nature of the sector. While Novo Nordisk and Eli Lilly are expected to maintain their dominant positions through 2030, the success of these smaller players could significantly alter the competitive landscape. If forecasts materialize, these companies could experience substantial growth and deliver significant returns to shareholders, further emphasizing the lucrative potential of GLP-1RAs for both established industry leaders and innovative newcomers.
